STOCK TITAN

Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Genenta Science (NASDAQ: GNTA) announces CEO Pierluigi Paracchi's participation as a speaker at the Italy-U.S. meeting on 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' at the U.S. Senate on October 25th, 2024. The event, organized by the U.S. National Security Commission on Emerging Biotechnology and Italian Embassy, features distinguished speakers including Michelle Rozo, Mariangela Zappia, and Patrick Soon-Shiong.

As moderator of the Italian Working Group on Internationalization of Biotech Sector (NWTIB), Paracchi will present the Interim Report, emphasizing the strategic importance of biotechnologies post-pandemic and Italy's role in preserving and advancing these innovations while attracting international investments.

Genenta Science (NASDAQ: GNTA) annuncia la partecipazione del CEO Pierluigi Paracchi come relatore all'incontro Italia-Stati Uniti su 'Investimenti e Strategie Transfrontaliere nel Settore Biotech: Una Prospettiva Transatlantica' presso il Senato degli Stati Uniti il 25 ottobre 2024. L'evento, organizzato dalla Commissione Nazionale per la Sicurezza degli Stati Uniti sulle Biotecnologie Emergenti e dall'Ambasciata Italiana, presenta relatori di spicco tra cui Michelle Rozo, Mariangela Zappia e Patrick Soon-Shiong.

In qualità di moderatore del Gruppo di Lavoro Italiano sull'Internazionalizzazione del Settore Biotech (NWTIB), Paracchi presenterà il Rapporto Intermedio, sottolineando l'importanza strategica delle biotecnologie nel periodo post-pandemia e il ruolo dell'Italia nel preservare e far progredire queste innovazioni attirando investimenti internazionali.

Genenta Science (NASDAQ: GNTA) anuncia la participación del CEO Pierluigi Paracchi como ponente en la reunión Italia-EE.UU. sobre 'Inversión y Estrategias Transfronterizas en el Sector Biotecnológico: Una Perspectiva Transatlántica' en el Senado de EE.UU. el 25 de octubre de 2024. El evento, organizado por la Comisión de Seguridad Nacional de EE.UU. sobre Biotecnologías Emergentes y la Embajada Italiana, contará con distinguidos oradores, incluyendo a Michelle Rozo, Mariangela Zappia y Patrick Soon-Shiong.

Como moderador del Grupo de Trabajo Italiano sobre Internacionalización del Sector Biotecnológico (NWTIB), Paracchi presentará el Informe Interino, enfatizando la importancia estratégica de las biotecnologías en el periodo post-pandemia y el papel de Italia en la preservación y el avance de estas innovaciones mientras atrae inversiones internacionales.

제넨타 사이언스 (NASDAQ: GNTA)는 CEO Pierluigi Paracchi가 2024년 10월 25일 미국 상원에서 열리는 '생명공학 분야의 국경 간 투자 및 전략: 대서양 간 관점'에 연사로 참여한다고 발표했습니다. 이 행사는 미국 신흥 생명공학 국가안보 위원회와 이탈리아 대사관이 주최하며, Michelle Rozo, Mariangela Zappia, 그리고 Patrick Soon-Shiong을 포함한 저명한 연사들이 참여합니다.

이탈리아 생명공학 부문 국제화 워킹 그룹(NWTIB)의 중재자로서, Paracchi는 중간 보고서를 발표하며 팬데믹 이후 생명공학의 전략적 중요성을 강조하고, 이탈리아의 혁신을 보존하고 발전시키며 국제 투자를 유치하는 데 있어 이탈리아의 역할을 강조할 것입니다.

Genenta Science (NASDAQ: GNTA) annonce la participation du PDG Pierluigi Paracchi en tant qu'intervenant lors de la rencontre Italie-États-Unis sur 'Investissements et Stratégies Transfrontalières dans le Secteur de la Biotechnologie: Une Perspective Transatlantique' au Sénat des États-Unis le 25 octobre 2024. L'événement, organisé par la Commission de la Sécurité Nationale des États-Unis sur les Biotechnologies Émergentes et l'Ambassade d'Italie, met en avant des intervenants distingués tels que Michelle Rozo, Mariangela Zappia et Patrick Soon-Shiong.

En tant que modérateur du Groupe de Travail Italien sur l'Internationalisation du Secteur Biotech (NWTIB), Paracchi présentera le Rapport Intermédiaire, soulignant l'importance stratégique des biotechnologies après la pandémie et le rôle de l'Italie dans la préservation et la promotion de ces innovations tout en attirant des investissements internationaux.

Genenta Science (NASDAQ: GNTA) gibt die Teilnahme von CEO Pierluigi Paracchi als Referent bei dem Treffen Italien-USA über 'Grenzüberschreitende Investitionen und Strategien im Biotechnologiesektor: Eine transatlantische Perspektive' im US-Senat am 25. Oktober 2024 bekannt. Die Veranstaltung, organisiert von der US-Kommission für nationale Sicherheit im Bereich aufstrebender Biotechnologie und der italienischen Botschaft, wird hochkarätige Referenten wie Michelle Rozo, Mariangela Zappia und Patrick Soon-Shiong präsentieren.

Als Moderator der italienischen Arbeitsgruppe zur Internationalisierung des Biotechnologiesektors (NWTIB) wird Paracchi den Zwischenbericht vorstellen, in dem er die strategische Bedeutung der Biotechnologie nach der Pandemie und die Rolle Italiens bei der Bewahrung und Förderung dieser Innovationen sowie der Anwerbung internationaler Investitionen hervorhebt.

Positive
  • None.
Negative
  • None.

MILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” scheduled at 2.00 PM on October 25th, 2024 at the U.S. Senate - Washington, D.C. The event is organized by the U.S. National Security Commission on Emerging Biotechnology (NSCEB) and the Italian Embassy in the U.S.

The upcoming mission to Washington, D.C. is part of the strategic plan of the Italian Working Group on the Internationalization of the Biotech Sector (NWTIB) established by the Deputy Prime Minister and Minister of Foreign Affairs Antonio Tajani. Pierluigi Paracchi, as a moderator of the NWTIB, will present the recently released Interim Report (full report in English HERE).

Keynote Speakers:
Michelle Rozo, Vice Chair of the National Security Commission on Emerging Biotechnology (NSCEB)
Mariangela Zappia, Ambassador of Italy to the U.S.
Megan Frisk, Ph.D., Director Division of lnternational Affairs at the Advanced Research Projects Agency for Health (ARPA-H)
Mauro Battocchi, Director General for the Promotion of ltaly at the ltalian Ministry of Foreign Affairs
Pierluigi Paracchi, CEO and Co-founder of Genenta Science (Nasdaq: GNTA)
Patrick Soon-Shiong, M.D., Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman of ImmunityBio, Executive Chairman of California Times
Andrea llly, Chair at lllycaffè

From the CEO's Desk: Pierluigi Paracchi stated: “With the pandemic, biotechnologies have been elevated to strategic technologies by leading global nations. Italy, with its rich scientific heritage, must ensure that these innovations are rapidly and concretely applied, while preserving them as national assets. At the same time, the internationalization of the sector, collaboration with partner countries, and the attraction of foreign investments are crucial for ensuring competitive growth. Government investment agencies should focus on strategic operations of a competitive scale, aligning with the international standards of countries already leading the sector.”

Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective

About Genenta and Temferon
Genenta (www.genenta.com) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon is currently under investigation in a clinical trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter (uMGMT-GBM) and expects to commence a Phase 1 clinical trial for metastatic Renal Cell Carcinoma (mRCC). Temferon is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology.

Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of its ongoing clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its expected clinical trial for metastatic RCC or any related studies, as well as Genenta’s ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

Genenta Media
Tiziana Pollio, Mobile: +39 348 23 15 143
Email: tiziana.pollio@genenta.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0eb35962-e4cc-415b-8ed7-30daa2c62281


FAQ

When is Genenta Science (GNTA) presenting at the U.S. Senate meeting?

Genenta Science's CEO will present at the U.S. Senate meeting on October 25th, 2024, at 2:00 PM in Washington, D.C.

What is the topic of the U.S. Senate meeting where Genenta (GNTA) is presenting?

The meeting's topic is 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective'

Who are the key speakers at the U.S. Senate biotech meeting featuring Genenta (GNTA)?

Key speakers include Michelle Rozo (NSCEB), Mariangela Zappia (Italian Ambassador), Pierluigi Paracchi (Genenta CEO), and Patrick Soon-Shiong (ImmunityBio)

What role does Genenta's (GNTA) CEO have in the Italian biotech working group?

Pierluigi Paracchi serves as a moderator of the Italian Working Group on the Internationalization of the Biotech Sector (NWTIB)

Genenta Science S.p.A. American Depositary Shares

NASDAQ:GNTA

GNTA Rankings

GNTA Latest News

GNTA Stock Data

91.08M
11.21M
38.68%
7.78%
0.03%
Biotechnology
Healthcare
Link
United States of America
Milan